Tezosentan in Pulmonary Arterial Hypertension



Status:Terminated
Conditions:High Blood Pressure (Hypertension)
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:7/11/2018
Start Date:August 2010
End Date:September 2011

Use our guide to learn which trials are right for you!

Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines

Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the
Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With
Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin
Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines


Inclusion Criteria:

1. Signed informed consent

2. Male and female patients 18 years of age or older

3. Patients with PAH according to one of the following subgroups of the Venice
Classification Group 1:

- Idiopathic (iPAH), or

- Familial/heritable (FPAH), or

- Associated (APAH) with collagen vascular disease

4. Modified NYHA functional class II-III

5. Documented hemodynamic diagnosis of PAH by right heart catheterization at Baseline:

- Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and

- Resting mean PVR ≥ 240 dyn•s•cm-5 and

- Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg

Exclusion Criteria:

1. Patients with PAH in Venice Classification Groups 2-5, and PAH Group 1 subgroups not
covered by inclusion criterion no. 3

2. Hypotensive patients (systemic systolic blood pressure < 100 mmHg)

3. Patients with body weight < 50 kg (110 lbs)

4. Patients with moderate or severe hepatic impairment (Child-Pugh B and C)

5. Patients with clinically significant chronic renal insufficiency (serum creatinine >
2.5mg/dL / 221µmol/L)

6. Patients who have received any endothelin receptor antagonist (ERA) and/or any
phosphodiesterase-5 (PDE-5) inhibitor within 28 days of Baseline

7. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g.,
treprostinil, iloprost) within 28 days of Baseline

8. Patients who have received any investigational drugs within 28 days of Baseline

9. Patients who have received cyclosporine A or tacrolimus within 28 days of Baseline

10. Psychotic, addictive or other disorder limiting the ability to provide informed
consent or to comply with the study

11. Life expectancy less than 12 months

12. Females who are lactating or pregnant or females who are not using a reliable method
of birth control (failure rate less than 1% per year) during the study and for at
least one month after study drug intake

13. Known hypersensitivity to any of the excipients of the drug formulation

14. Patients with positive response to vasoreactivity test
We found this trial at
3
sites
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Paris, Clamart 92141
?
mi
from
Paris,
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials